PerkinElmer, Inc. (PKI) Shares Sold by Globeflex Capital L P
Globeflex Capital L P trimmed its holdings in shares of PerkinElmer, Inc. (NYSE:PKI) by 14.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,880 shares of the medical research company’s stock after selling 3,170 shares during the quarter. Globeflex Capital L P’s holdings in PerkinElmer were worth $1,286,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of PKI. Waldron LP purchased a new stake in shares of PerkinElmer during the first quarter valued at approximately $233,000. Russell Investments Group Ltd. increased its position in shares of PerkinElmer by 13.4% during the first quarter. Russell Investments Group Ltd. now owns 21,459 shares of the medical research company’s stock valued at $1,245,000 after acquiring an additional 2,531 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of PerkinElmer by 143.5% during the first quarter. Canada Pension Plan Investment Board now owns 5,600 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 3,300 shares during the last quarter. LS Investment Advisors LLC increased its position in shares of PerkinElmer by 36.9% during the first quarter. LS Investment Advisors LLC now owns 2,817 shares of the medical research company’s stock valued at $164,000 after acquiring an additional 759 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in shares of PerkinElmer by 15.0% during the first quarter. UBS Asset Management Americas Inc. now owns 73,057 shares of the medical research company’s stock valued at $4,242,000 after acquiring an additional 9,507 shares during the last quarter. 91.47% of the stock is owned by institutional investors.
PerkinElmer (NYSE:PKI) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $547.00 million for the quarter, compared to analysts’ expectations of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS.
The company also recently declared a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.41%. PerkinElmer’s payout ratio is 8.46%.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/25/perkinelmer-inc-pki-shares-sold-by-globeflex-capital-l-p.html.
A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “hold” rating on shares of PerkinElmer in a research report on Sunday, July 16th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price target for the company in a research report on Wednesday, July 19th. Piper Jaffray Companies increased their price target on PerkinElmer to $80.00 and gave the company an “overweight” rating in a research report on Tuesday, July 25th. Wells Fargo & Company assumed coverage on PerkinElmer in a research report on Thursday, July 13th. They set a “market perform” rating and a $72.00 price target for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $79.00 price target (up from $73.00) on shares of PerkinElmer in a research report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $67.50.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.